Neurotransmitter Levels in Children With Specific Learning Disorder

NCT07240142 | Completed

• 1 other identifier: SCÜ Child Psychiatry
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this clinical trial was to measure how specific neurotransmitter levels in children with Specific Learning Disorder (SLD) change compared to controls. The relationship between these markers and the measured markers will be determined both theoretically and experimentally using various neuropsychological tests. The fundamental questions it aims to answer are Did neurotransmitter levels increase or decrease in the patient group? Are the neurotransmitter levels measured in the neuropsychological tests related? Can the measured neurotransmitters be used to predict the disease? Participants: A single visit to the clinic, a blood sample, and neuropsychological tests will be administered on the same day.

Conditions

Specific Learning Disability; Healthy (Controls)

Keywords

Specific learning Disorder; Glutamate; L-arginine; nitric oxide; molecualr docking

Outcome Measures

Primary Outcomes (7)

• Mesurment of serum neurotransmitters levels

  Serum Glutamate Levels (measured in µmol/L by ELISA at baseline) Serum L-Arginine Levels (measured in µmol/L by ELISA at baseline) Serum Nitric Oxide (NO) Levels (measured in µmol/L by ELISA at baseline)

  6 months

• Verbal Comprehension Index (VCI)

  Change in Verbal Comprehension Index (VCI) score from baseline to 6 months.Points on a scale (range: 40-160; higher scores indicate better performance)

  6 month

• Perceptual Reasoning Index (PRI)

  Change in Perceptual Reasoning Index (PRI) score from baseline to 6 months. Change in Perceptual Reasoning Index (PRI) score from baseline to 6 months.

  6 months

• Working Memory Index (WMI)

  Change in Working Memory Index (WMI) score from baseline to 6 months. Points on a scale (range: 40-160; higher scores indicate better performance)

  6 months

• Processing Speed Index (PSI)

  Change in Processing Speed Index (PSI) score from baseline to 6 months. Points on a scale (range: 40-160; higher scores indicate better performance).

  6 months

• Stroop Test Performance

  Change in Stroop Test total errors, total time, and total corrections from baseline to 6 months.Seconds (for time) and number of errors/corrections; lower scores indicate better performance.

  6 months

• Full Scale IQ (FSIQ)

  Change in Full Scale IQ (FSIQ) score from baseline to 6 months.oints on a scale (range: 40-160; higher scores indicate better performance)

  6 months

Other Outcomes (2)

• Molecular docking analysis

  6 months

• ROC analysis performance of biomarkers

  6 months

Study Arms (1)

Collection of blood samples

EXPERIMENTAL

A 5 ml blood sample will be taken from the left arterial vein of the individuals in the study group, and serum will be obtained from it. The neurotransmitter concentrations specified in the serum samples will be measured with an ELISA test kit.

Procedure: Blood Product; Other: Elisa test

Interventions

Blood Product PROCEDURE

Collecting 5 ml blood samples from the left atrial vein, after that obtaining serum from it.

Collection of blood samples

Elisa test OTHER

Measurement of glutamate, nitric oxide, and L-arginine concentrations in the blood samples obtained using an ELISA test kit.

Collection of blood samples

Eligibility Criteria

• Age: 7 Years - 14 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)

You may qualify if:

• Study group: no additional mental disorder except a specific learning disability,
• The control group had no mental illness.
• Having no head injury or neurological illness for all groups.
• There is no drug that might possibly alter cognitive functions for all populations.

You may not qualify if:

• The study group had a mental disease other than a specific learning disability and ADHD.
• The control group had any mental condition.
• Having a head injury or neurological illness in all categories.
• Using drugs that may impair cognitive functioning in all groups those with additional diseases

Sponsors & Collaborators

• Dilara Ulger Ozbek: lead

Study Sites (1)

Sivas Cumhuriyet University

Sivas, Central, 58146, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Specific Learning Disorder

Condition Hierarchy (Ancestors)

Learning Disabilities; Communication Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Neurodevelopmental Disorders; Mental Disorders

Study Officials

• Dilara ULGER OZBEK, Dr.

  Cumhuriyet University

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Dr.

Model Details: Blood sample collection

Study Record Dates

• First Submitted: September 30, 2025
• First Posted: November 20, 2025
• Study Start: October 22, 2019
• Primary Completion: October 21, 2020
• Study Completion: April 16, 2021
• Last Updated: November 20, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)